Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles tagged with "Advocacy"

Rheumatology Research Foundation Investigators’ Meeting Shares Advancements Toward a Cure

  |  

The Rheumatology Research Foundation hosted the 9th annual Investigators’ Meeting in Atlanta on June 24–25. As a requirement for Foundation innovative research and pilot grant recipients, Foundation-funded investigators meet annually to provide updates and status reports on the work they are doing to advance treatments and cures for rheumatic diseases. More than 50 attendees enjoyed…

The ACR’s Workforce Study Group to Release 2015 Survey Results

Joan M. Von Feldt, MD, MSEd, FACR, FACP, & Eric L. Matteson, MD, MPH  |  

The ACR and its Rheumatology Research Foundation continue to work together to provide support for the rheumatology and patient communities. Both organizations are committed to advancing the field of rheumatology with a dedication to expanding the workforce. With a growing number of patients being diagnosed with a rheumatic disease and living longer with the disease,…

The ACR’s Advocacy at State Legislature Level in 2016 Focuses on Biosimilars, Step Therapy

  |  

A majority of state legislatures have concluded their work for 2016. The ACR’s state advocacy efforts continued to focus on policy benefiting rheumatologists and patients alike. The two dominant issues this year were biosimilar substitution and step therapy. Biosimilar Substitution Biosimilar substitution remains the most prevalent issue throughout the states. The ACR continues to monitor…

The ACR’s Collaborative Initiatives Promote Awareness of Lupus, Rheumatic Diseases

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  

When I began my tenure as ACR president this past November, I posited that it “takes a village” to grow and succeed in rheumatology’s rapidly changing environment. The ACR village includes volunteers who represent a diverse leadership pipeline reflecting the demographics of our younger members. It also includes the international rheumatology community that accounts for…

How Rheumatologists Can Engage Congress Locally, Advance Rheumatology

  |  

With limited time to spend away from your practice, you can still have an impact on issues important to Advancing Rheumatology! Below are several ways to have your voice heard, without ever leaving town. Set Up a Local Meeting with Your Elected Officials Every member of Congress has at least one local office in the…

Participate in Virtual Hill Meetings through the ACR

  |  

On May 12, ACR leaders representing the Board of Directors, the Affiliate Societies Council and the Committees on Government Affairs and RheumPAC took the ACR’s policy message to Capitol Hill. There is power in numbers, so we hope you will participate in your own Virtual Hill Day by visiting Legislative Action Center and letting your…

State of RheumPAC: 2015 Annual Report

Harry L. Gewanter, MD  |  

Dear Friends and Colleagues, With your strong support and commitment, RheumPAC has grown again for the eighth straight year, allowing us to do even more on your behalf. Not only did we exceed our original goal by raising more than $150,000. More importantly, these donations came from nearly 350 ACR and ARHP members—a new record….

Rheumatology Research Foundation Creates Five-Year Strategic Plan

  |  

Dramatic advancements in research toward prevention and cure are at risk, as federal research funding for rheumatic diseases has declined by 40% over the past five years. With that, an alarming number of rheumatologists are preparing for retirement. To stop this worrying trend, a strategic plan for the next five years was developed to complement…

Opinion: Politics Should Not Trump Science in Medicine

John A. Goldman, MD  |  

I tell my patients there are three types of science: 1) investigative science, which sometimes gets it right; 2) science in the courtroom, which is junk science; and 3) science in Washington, D.C., which is political science. Our decisions are based on art and science; our patients’ medications are brought to market based on science….